晚期胃肠道类癌肿瘤的全身治疗

Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.

作者信息

Mulvey Claire K, Bergsland Emily K

机构信息

Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, Box 0119, San Francisco, CA 94143, USA.

Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, 1600 Divisadero Street, A727, San Francisco, CA 94115, USA.

出版信息

Hematol Oncol Clin North Am. 2016 Feb;30(1):63-82. doi: 10.1016/j.hoc.2015.09.002.

DOI:10.1016/j.hoc.2015.09.002

PMID:26614369

Abstract

Well-differentiated gastrointestinal neuroendocrine tumors (GINETs) tend to be slow growing, but treatment of advanced disease remains a challenge. Somatostatin analogues (SSAs) are considered standard therapy for carcinoid syndrome. SSAs delay tumor progression in advanced well-differentiated gastroenteropancreatic NETs. Cytotoxic chemotherapy and interferon play a limited role in the treatment of nonpancreatic GINETs. There is no standard approach to treatment of patients with disease progression. Identification of systemic agents with antitumor activity in advanced disease remains an unmet medical need. Enrollment to clinical trials is encouraged; potential therapeutic targets include the vascular endothelial growth factor and mammalian target of rapamycin signaling pathways.

摘要

高分化胃肠道神经内分泌肿瘤（GINETs）往往生长缓慢，但晚期疾病的治疗仍然是一项挑战。生长抑素类似物（SSAs）被认为是类癌综合征的标准疗法。SSAs可延缓晚期高分化胃肠胰神经内分泌肿瘤（NETs）的肿瘤进展。细胞毒性化疗和干扰素在非胰腺GINETs的治疗中作用有限。对于疾病进展的患者，尚无标准的治疗方法。确定晚期疾病中具有抗肿瘤活性的全身药物仍然是未满足的医疗需求。鼓励参加临床试验；潜在的治疗靶点包括血管内皮生长因子和雷帕霉素信号通路的哺乳动物靶点。